Cantharidin Medicine 04 June 2026 Extended indication Cantharidin monotherapy for treatment of Molluscum contagiosum in children, adolescents, adults and elderly Therapeutic value Total cost Registration phase Clinical trials Product Active substance Cantharidin Domain Infectious diseases Reason of inclusion New medicine (specialité) Main indication Viral infections other Extended indication Cantharidin monotherapy for treatment of Molluscum contagiosum in children, adolescents, adults and elderly Current proprietary name Already available biosimilars / generics Proprietary name Ycanth Manufacturer Portfolio holder Verrica Mechanism of action Other Route of administration Cutaneous Therapeutical formulation Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Werkingsmechanisme: activatie van serine‑proteasen Registration Registration route Centralised (EMA) Type of trajectory Particularity ATMP Submission date November 2026 Expected Registration December 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value Substantiation Op dit moment wordt behandeling van mollusca contagiosa niet aangeraden (1) Duration of treatment Frequency of administration Dosage per administration References NCT03377790 (CAMP-1), NCT03377803 (CAMP-2)/ (1) NHG behandelrichtlijn mollusca contagiosa Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References drugs.com Additional remarks Er is geen Nederlandse lijstprijs bekend. In de Verenigde Staten kost een 0,7% flacon $710,22. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions No Indication extensions References Additional remarks Other information Additional remarks